Organisation paid for research Program year 2025 Source: CMS Open Payments

Signature Gyn Services PLLC

Neither a doctor nor a teaching hospital

Research payments

$1,686,244

355 payments

Through program year 2025, Signature Gyn Services PLLC is reported as receiving $1,686,244 in research payments, across 355 payments.

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$79,552	33
2024	Research	$55,856	27
2023	Research	$284,646	76
2022	Research	$697,105	68
2021	Research	$191,773	46
2020	Research	$194,760	60
2019	Research	$182,552	45

Breakdown

Who paid Research payments · program years 2019–2025

Abbott Laboratories $781,215 27 payments
AbbVie, Inc. $517,617 164 payments
Bayer HealthCare Pharmaceuticals Inc. $210,383 97 payments
Sumitomo Pharma America, Inc. $91,097 37 payments
Myovant Sciences GmbH $38,917 17 payments
Mitsubishi Tanabe Pharma Development America, Inc. $28,127 3 payments
GlaxoSmithKline, LLC. $18,887 10 payments

Studies the money was for Research payments · program years 2019–2025

Alinity m HR HPV Specimen Collection Study from Women Referred to Colposcopy $506,855 13 payments
M14-702 $179,490 33 payments
BAY1002670 Long term Safety vs SoC $146,691 62 payments
Alinity m HR HPV Self-Collect Study (CE) Protocol for Specimen Collection from Subjects Undergoing Routine Cervical Cancer Screening $130,470 8 payments
Alinity m HR HPV Specimen Collection Study from Women Undergoing Routine Cervical cancer Screening $120,123 4 payments
M16-824 $61,964 8 payments
A Phase 3b Study to Evaluate the Safety and Efficacy of Elagolix in Combination with Combined Oral Contraceptives in Premenopausal Women with Documented Endometriosis and Associated Moderate to Severe Pain $47,932 12 payments
Study of Oral Elagolix Tablets in Combination With Combined Oral Contraceptive Capsules Tablets to Assess Dysmenorrhea Response in Adult Female Participants With Endometriosis and Associated Moderate to Severe Pain $46,713 18 payments
A Phase 3 Study to Evaluate the Safety and Efficacy of Elagolix in Combination with Estradiol/Norethindrone Acetate in Subjects with Moderate to Severe Endometriosis-Associated Pain $41,249 32 payments
A Phase 3, Single-Arm, Open-Label Study to Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are 18 to 50 Years of Age and at Risk for Pregnancy $37,226 17 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.